Cardiff Oncology Inc (XE7C.BE)
| Previous close | 3.0950 |
| Open | 3.1450 |
| Bid | 3.1550 x 0 |
| Ask | 3.3050 x 0 |
| Day's range | 3.1450 - 3.2300 |
| 52-week range | 0.8940 - 5.8000 |
| Volume | |
| Avg. volume | 2 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCardiff Oncology to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024. Details of the presentations can be found below. H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQLocation: The Nasdaq Headquarters, New York CityPresenter: Mark Erlander, CEOF
Simply Wall St.Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
Cardiff Oncology ( NASDAQ:CRDF ) First Quarter 2024 Results Key Financial Results Net loss: US$10.0m (loss narrowed by...
- GlobeNewswire
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib’s antitumor activity both as a single agent and in combination, highlighting its broad activity across all mCRC - - In SCLC and ovarian cancer, preclinical data presented at AACR highlighted onvan
